Latest news with #KenvueInc
Business Wire
7 days ago
- Business
- Business Wire
Kenvue Debuts on Fortune 500 List
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Tylenol®, Neutrogena® and Listerine®, today announced it has made the prestigious Fortune 500 list for the first time since becoming a fully independent company. With 2024 full year sales of $15.5 billion, Kenvue is listed at number 281. The company's debut is a testament to the power of its iconic brands and deep commitment to improving the health and well-being of consumers globally through science-backed, insights-led innovation. 'Being named to the Fortune 500 list marks a significant milestone for Kenvue,' said Thibaut Mongon, Chief Executive Officer. 'Recognitions like this validate the hard work and dedication of our Kenvuers, while also further propelling our desire to become the undisputed global leader in consumer health. We are honored to join this elite group of companies and look forward to continuing our journey of growth and impact.' Operating in over 165 countries worldwide, Kenvue is comprised of a curated portfolio of Essential Health, Self Care, and Skin Health & Beauty brands reaching approximately 1.2 billion people daily. Its global workforce of more than 20,000 purpose-led, values-based Kenvuers are driven to make a meaningful impact on the health of people and the planet. By combining the power of science with deep human insights and cutting-edge technology, Kenvue is poised to use its size and scale as a Fortune 500 company to take a leadership role in the wellness revolution - placing its products and solutions at the center of everyday care rituals, today and into the future. Now in its 71st year, the Fortune 500 is Fortune magazine's annual list of the 500 largest U.S. companies ranked by total revenues for their respective fiscal years. The list is compiled using the most recent revenue figures and includes both public and private companies. About Kenvue Kenvue Inc. is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage, our iconic brands, including Aveeno®, BAND-AID® Brand, Johnson's®, Listerine®, Neutrogena® and Tylenol®, are science-backed and recommended by healthcare professionals around the world. At Kenvue, we realize the extraordinary power of everyday care. Our teams work every day to put that power in consumers' hands and earn a place in their hearts and homes. Learn more at
Yahoo
18-05-2025
- Business
- Yahoo
Kenvue Inc. (KVUE) Emerges as Hedge Fund Favorite with Fresh Q1 2025 Buys
Daniel Loeb's hedge fund, Third Point, has taken a significant position in Kenvue Inc. (NYSE:KVUE), acquiring 8.9 million shares valued at over $213 million, signaling interest in potential mergers or strategic shifts aimed at boosting shareholder returns. Meanwhile, Toms Capital Investment Management also made a notable move during the first quarter, purchasing 14.4 million shares worth $345.6 million. According to its 13F filing, Kenvue Inc. (NYSE:KVUE) is now the firm's second-largest holding, accounting for 10.5% of its portfolio. Sources familiar with the matter said Toms Capital is encouraging Kenvue to explore strategic options, including the potential sale of the company or parts of it. The New Jersey-based consumer health firm became fully independent in 2023 following its spin-off from Johnson & Johnson. While the separation raised some initial uncertainty, the company shows promise of emerging as a solid standalone business, thanks in part to the rapid growth of its Skin Health and Beauty divisions. In addition, Kenvue Inc. (NYSE:KVUE) has inherited Johnson & Johnson's track record of dividend growth after becoming independent. In 2024, the company hiked its quarterly dividend by 2.5%, which took its dividend growth streak to 63 years. It currently pays a quarterly dividend of 0.205 per share and has a dividend yield of 3.39%, as of May 18. While we acknowledge the potential of KVUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
18-05-2025
- Business
- Yahoo
Kenvue Inc. (KVUE) Emerges as Hedge Fund Favorite with Fresh Q1 2025 Buys
Daniel Loeb's hedge fund, Third Point, has taken a significant position in Kenvue Inc. (NYSE:KVUE), acquiring 8.9 million shares valued at over $213 million, signaling interest in potential mergers or strategic shifts aimed at boosting shareholder returns. Meanwhile, Toms Capital Investment Management also made a notable move during the first quarter, purchasing 14.4 million shares worth $345.6 million. According to its 13F filing, Kenvue Inc. (NYSE:KVUE) is now the firm's second-largest holding, accounting for 10.5% of its portfolio. Sources familiar with the matter said Toms Capital is encouraging Kenvue to explore strategic options, including the potential sale of the company or parts of it. The New Jersey-based consumer health firm became fully independent in 2023 following its spin-off from Johnson & Johnson. While the separation raised some initial uncertainty, the company shows promise of emerging as a solid standalone business, thanks in part to the rapid growth of its Skin Health and Beauty divisions. In addition, Kenvue Inc. (NYSE:KVUE) has inherited Johnson & Johnson's track record of dividend growth after becoming independent. In 2024, the company hiked its quarterly dividend by 2.5%, which took its dividend growth streak to 63 years. It currently pays a quarterly dividend of 0.205 per share and has a dividend yield of 3.39%, as of May 18. While we acknowledge the potential of KVUE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KVUE and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Standard
09-05-2025
- Business
- Business Standard
Shares poised to take flight on tailwinds from global optimism
GIFT Nifty: GIFT Nifty May 2025 futures were trading 93.50 points higher in early trade, suggesting a strong opening for the Nifty 50. India-Pakistan Tensions Escalate: Amid rising tensions with Pakistan, India has ramped up security in New Delhi by deploying additional forces and intensifying police surveillance. The move follows Indias successful neutralization of multiple Pakistani drone and missile attacks targeting military sites in Jammu, Pathankot, and Udhampur, along with similar threats in 15 other northern and western locations. No casualties were reported. A major infiltration attempt along the International Border in Samba was also foiled. Meanwhile, Pakistan conducted heavy shelling along the Line of Control in Poonch, Rajouri, Uri, and Chowkibal Kupwara, resulting in property damage and the reported death of a woman in Uri. The developments come in the aftermath of the April 22 Pahalgam terror attack, which claimed 26 lives. Institutional Flows: Foreign portfolio investors (FPIs) bought shares worth 2,007.96 crore, while domestic institutional investors (DIIs) were net sellers to the tune of Rs 596.25 crore in the Indian equity market on 8 May 2025, provisional data showed. According to NSDL data, FPIs have bought shares worth Rs 10868.59 crore in the secondary market during May 2025 (so far). This follows their purchase of shares worth Rs 3243.03 crore in April 2024. Global Markets: Asian stocks posted gains on Friday as investors awaited Chinas trade data for April. Concerns persisted over a potential deceleration in Chinese export growth due to recently imposed U.S. tariffs. Additionally, market sentiment remained cautious amid uncertainty surrounding the outcome of scheduled trade discussions between the United States and China in Switzerland. On Wall Street, major indices advanced after U.S. President Donald Trump outlined a preliminary trade agreement with the United Kingdom the first such deal since the U.S. halted its broader "reciprocal" tariff measures in April. According to the initial framework, the U.S. will maintain a 10% tariff on UK imports. In return, the UK will reduce its tariff rate from 5.1% to 1.8% and offer expanded access to U.S. goods. Imports of steel and aluminum from the UK will also be exempt from the existing 25% U.S. levy. While investors interpreted the framework as a sign of potential future trade progress, the lack of a signed agreement or detailed documentation limited market certainty. President Trump indicated that final terms are still being finalized and are expected to be formalized in the coming weeks. The Dow Jones Industrial Average rose by 0.62%, the S&P 500 increased 0.58%, and the Nasdaq Composite climbed 1.07%. In corporate earnings news, shares of Kenvue Inc gained 4% following better-than-expected first-quarter results. Tapestry Inc rose nearly 4% after the company raised its annual earnings outlook. Conversely, Restaurant Brands International declined slightly after reporting revenue and profit below estimates. Shares of Arm Holdings fell 6% following the release of weaker-than-expected guidance. The number of Americans filing new applications for unemployment benefits fell more than expected last week, as initial claims for state unemployment benefits dropped 13,000 to a seasonally adjusted 228,000 for the week ended May 3, the Labor Department said on Thursday. Domestic Market: The headline equity indices slipped into the red on Thursday, as rising geopolitical tensions and cautious global cues dampened investor sentiment. Tensions flared after Indian forces reportedly neutralised an air defence system in Lahore, keeping markets on edge. Adding to the nervousness, US Fed Chair Jerome Powell warned that persistent tariff hikes could slow economic growth and fuel long-term inflation. His comments on rising inflation and labour market risks further spooked global investors. The S&P BSE Sensex slipped 411.97 points or 0.51% to 80,334.81. The Nifty 50 index fell 140.60 points or 0.58% to 24,273.80.
Yahoo
08-05-2025
- Business
- Yahoo
Neutrogena-Maker Kenvue Beats Profit Forecast, Ups Sales Outlook (UPDATED)
Editor's Note: Self care segment revenue growth updated Consumer health company Kenvue Inc. (NYSE:KVUE) on Thursday reported first-quarter 2025 sales of $3.74 billion, beating the consensus of $3.68 billion. Sales decreased 3.9% year over year, reflecting a 1.2% organic sales decline and a 2.7% foreign currency headwind. The organic sales decline was driven by 0.3% unfavorable value realization, reflecting planned strategic price investments, and a 0.9% volume decline. Some of Kenvue's most iconic brands include Aveeno, BAND-AID Brand, Johnson's, Listerine, Neutrogena, and Tylenol. Gross profit margin was 58.0% vs. 57.6% a year ago. Adjusted gross profit margin contracted 20 basis points vs. the prior year period to 60%.Operating income margin was 14.9% vs. 14.1%. Adjusted operating income margin was 19.8% vs. 22.0% in the prior year period. The self-care segment recorded $1.67 billion in net sales, down 1.8% year over year (up 0.3% on organic basis). The skin health and beauty segment recorded a 7% drop in first-quarter net sales to $977 million. Essential Health segment sales decreased around 4% to $1.09 billion. 'In Q1, our teams executed our plans while continuing to navigate an evolving macro and consumer environment,' said Thibaut Mongon, CEO. 'We are committed and focused on activating our brands while staying agile and flexible to accelerate sustainable, profitable growth.' Guidance: Kenvue updated its fiscal 2025 outlook to reflect current foreign exchange rates and the estimated impact of higher costs due to tariffs. The company expects: Net sales increase of +1% to +3% (-1% to +1% prior) year-over-year, with organic sales growth of +2% to +4 (unchanged) and a ~1% headwind from foreign currency translation (earlier expected around 3%). Adjusted operating income margin is expected to decline year over year, reflecting the estimated impact of tariffs. Earlier, the company expected improvement year over year. Adjusted diluted earnings per share are expected to be about flat year over year, including a low-single-digit negative impact from foreign currency. In February, Kenvue expected flat to +2% year-over-year Adjusted diluted earnings per share growth, including a mid-single-digit unfavorable impact from foreign currency. The company is working to reduce tariffs' financial impact through several mitigation actions. On Thursday, Kenvue appointed Amit Banati as the company's CFO, effective May 12, 2025. Mr. Banati will succeed Paul Ruh. In April, Kenvue announced a five-year collaboration with Microsoft to establish a strong foundation for transforming digital operations through advanced Artificial Intelligence (AI) technologies. These technologies include machine-enabled collaboration, predictive analytics, smart agents, digital twins, and generative AI. By advancing predictive and AI-assisted capabilities, Kenvue aims to deliver enhanced consumer experiences, increased productivity, and sustained growth. Over the next five years, Kenvue will scale its use of Microsoft Azure to capitalize on its wide range of services, including data analytics and AI. Price Action: KVUE stock is up 6.30% at $24.57 at the last check on Thursday. Photo by Colleen Michaels via Shutterstock UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article Neutrogena-Maker Kenvue Beats Profit Forecast, Ups Sales Outlook (UPDATED) originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
